Amorfix Life Sciences' test detects scrapie prions in bllod ofg scrapie-infected sheep
"These initial results demonstrate the ability of our diagnostic technology to identify endogenous prions which is important for the commercialization of our variant Creutzfeldt-Jacob Disease (vCJD) diagnostic blood test," said Dr. George Adams, CEO of Amorfix Life Sciences. "These data plus additional results that we will generate will be included in the regulatory submission of a self-declared CE mark for the commercialization of the EP-vCJD(tm) test. Moreover, while the EP-vCJD(tm) test is our lead diagnostic candidate, these results present a new commercial opportunity for the testing of all sheep and selective removal of infected animals."
Amorfix correctly scored 11 out of 12 positive samples and 7 out of 8 negative samples. It is unknown if all sheep with scrapie have endogenous prions in their blood. At present there is no effective blood diagnostic test that can identify scrapie prions in sheep, according to the company.
Most read news
Organizations
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
Most read news
More news from our other portals
See the theme worlds for related content
Topic world Diagnostics
Diagnostics is at the heart of modern medicine and forms a crucial interface between research and patient care in the biotech and pharmaceutical industries. It not only enables early detection and monitoring of disease, but also plays a central role in individualized medicine by enabling targeted therapies based on an individual's genetic and molecular signature.
Topic world Diagnostics
Diagnostics is at the heart of modern medicine and forms a crucial interface between research and patient care in the biotech and pharmaceutical industries. It not only enables early detection and monitoring of disease, but also plays a central role in individualized medicine by enabling targeted therapies based on an individual's genetic and molecular signature.